Peptide Cancer Vaccine Market: By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine, Others), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others), and Geography.

Purchase Option

$ 4400
$ 6600
$ 8900

Peptide Cancer Vaccine Market size was valued at USD 547.6 million in 2022, It is expected to reach a value of USD 1,501.5 million by 2029, growing at a CAGR of 15.5%  from 2023 to 2029. The global market provides a detailed overview, which has been segmented by type, and application. The peptide cancer vaccine market has been segmented into Multivalent Peptide Vaccines, Peptide Cocktail Types, Personalized Peptide Vaccines, Peptide-Pulsed Dendritic Cancer Vaccines, Hybrid Peptide Vaccine, and Others. The peptide cocktail type segment is likely the most significant and fastest-growing in terms of type. Based on the application, the peptide cancer vaccine is segmented into Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Others. According to Precision Business Insights, the breast cancer segment is predicted to register the fastest growth rate during the forecast period.

Peptide Cancer Vaccine Market Key Development:

In December 2021, ISA pharmaceuticals presented key learnings in cancer vaccine development in an educational session at the ESMO Immune-Oncology Congress 2021.

Peptide Cancer Vaccine Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

15.5%

Largest Market

North America

Fastest Growing Market

Asia-Pacific
Peptide Cancer Vaccine Market Dynamics

The ability to quickly synthesize, prepare and use peptide vaccines, their use in clinical settings, and adaptability to changing antigens. Reduced risk of anaphylaxis caused by antigens are benefits that are anticipated to drive market growth for peptide cancer vaccines shortly.

Peptide Cancer Vaccine Market Segmentation

By Type
  • Multivalent Peptide Vaccine,
  • Peptide Cocktail Type,
  • Personalized Peptide Vaccine,
  • Peptide-Pulsed Dendritic Cancer Vaccine,
  • Hybrid Peptide Vaccine,
  • Others
By Application
  • Breast Cancer,
  • Lung Cancer,
  • Melanoma,
  • Prostate Cancer and
  • Others

Frequently Asked Questions

The peptide cancer vaccine market size was valued at USD 547.6 million in 2022

The peptide cancer vaccine market key players are: Antigen Express BioLife Science Boston Biomedical Enzo Life Science Galena Biopharma Generex Biotechnology Generex Biotechnology Corporation Immatics Biotechnologies Immunomedics ISA Pharmaceuticals OncoTherapy Science Sellas TapImmune

The peptide cancer vaccine market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1. Executive Summary
2. Global Peptide Cancer Vaccine Market Introduction
2.1. Global Peptide Cancer Vaccine Market Taxonomy
2.2. Global Peptide Cancer Vaccine Market Definitions
2.2.1. By Type
2.2.2. By Application
2.2.3. By Region
3. Global Peptide Cancer Vaccine Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Peptide Cancer Vaccine Market Dynamic Factors - Impact Analysis
3.6. Global Peptide Cancer Vaccine Market Competition Landscape
4. Global Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Peptide Cancer Vaccine Market, By Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
5.1. Multivalent Peptide Vaccine
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Peptide Cocktail Types
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Personalized Peptide Vaccine
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Peptide-Pulsed Dendritic Cancer Vaccine
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Hybrid Peptide Vaccine
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. Global Peptide Cancer Vaccine Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
6.1. Breast Cancer
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Lung Cancer
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Melanoma
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Prostate Cancer
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Others
6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. Global Peptide Cancer Vaccine Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
7.1. North America
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia-Pacific
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
7.6. Global Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Region, 2023 - 2029
8. North America Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
8.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.1.1. Multivalent Peptide Vaccine
8.1.2. Peptide Cocktail Type
8.1.3. Personalized Peptide Vaccine
8.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
8.1.5. Hybrid Peptide Vaccine
8.1.6. Others
8.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
8.2.1. Breast Cancer
8.2.2. Lung Cancer
8.2.3. Melanoma
8.2.4. Prostate Cancer
8.2.5. Others
8.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
8.3.1. USA
8.3.2. Canada
8.4. North America Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029
8.5. North America Peptide Cancer Vaccine Market Dynamics Trends
9. Europe Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
9.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Multivalent Peptide Vaccine
9.1.2. Peptide Cocktail Type
9.1.3. Personalized Peptide Vaccine
9.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
9.1.5. Hybrid Peptide Vaccine
9.1.6. Others
9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Breast Cancer
9.2.2. Lung Cancer
9.2.3. Melanoma
9.2.4. Prostate Cancer
9.2.5. Others
9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.3.1. Germany
9.3.2. UK
9.3.3. France
9.3.4. Spain
9.3.5. Italy
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Europe Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029
9.5. Europe Peptide Cancer Vaccine Market Dynamics Trends
10. Asia-Pacific Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
10.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Multivalent Peptide Vaccine
10.1.2. Peptide Cocktail Type
10.1.3. Personalized Peptide Vaccine
10.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
10.1.5. Hybrid Peptide Vaccine
10.1.6. Others
10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Breast Cancer
10.2.2. Lung Cancer
10.2.3. Melanoma
10.2.4. Prostate Cancer
10.2.5. Others
10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. ASEAN
10.3.5. Australia & New Zealand
10.3.6. Rest of Asia-Pacific
10.4. Asia-Pacific Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029
10.5. Asia-Pacific Peptide Cancer Vaccine Market Dynamics Trends
11. Latin America Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
11.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Multivalent Peptide Vaccine
11.1.2. Peptide Cocktail Type
11.1.3. Personalized Peptide Vaccine
11.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
11.1.5. Hybrid Peptide Vaccine
11.1.6. Others
11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Breast Cancer
11.2.2. Lung Cancer
11.2.3. Melanoma
11.2.4. Prostate Cancer
11.2.5. Others
11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Argentina
11.3.4. Rest of Latin America
11.4. Latin America Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029
11.5. Latin America Peptide Cancer Vaccine Market Dynamics Trends
12. Middle East and Africa Peptide Cancer Vaccine Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) 
12.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Multivalent Peptide Vaccine
12.1.2. Peptide Cocktail Type
12.1.3. Personalized Peptide Vaccine
12.1.4. Peptide-Pulsed Dendritic Cancer Vaccine
12.1.5. Hybrid Peptide Vaccine
12.1.6. Others
12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Breast Cancer
12.2.2. Lung Cancer
12.2.3. Melanoma
12.2.4. Prostate Cancer
12.2.5. Others
12.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.3.1. Gulf Cooperation Council (GCC) Countries
12.3.2. Israel
12.3.3. South Africa
12.3.4. Rest of MEA
12.4. MEA Peptide Cancer Vaccine Market - Opportunity Analysis Index, By Type, Application, and Country, 2023 - 2029
12.5. MEA Peptide Cancer Vaccine Market Dynamics Trends
13. Competition Landscape 
13.1. Strategic Dashboard of Top Market Players
13.2. Company Profiles (Introduction, Financial Analysis, Type Offerings, Key Developments, Strategies, and SWOT Analysis)
13.2.1. Antigen Express
13.2.2. BioLife Science
13.2.3. Boston Biomedical
13.2.4. Enzo Life Science
13.2.5. Galena Biopharma
13.2.6. Generex Biotechnology
13.2.7. Generex Biotechnology Corporation
13.2.8. Immatics Biotechnologies
13.2.9. Immunomedics
13.2.10. ISA Pharmaceuticals
13.2.11. OncoTherapy Science
13.2.12. Sellas
13.2.13. TapImmune
13.2.14. VAXON Biotech
14. Research Methodology
15. Key Assumptions and Acronyms
  • Antigen Express
  • BioLife Science
  • Boston Biomedical
  • Enzo Life Science
  • Galena Biopharma
  • Generex Biotechnology
  • Generex Biotechnology Corporation
  • Immatics Biotechnologies
  • Immunomedics
  • ISA Pharmaceuticals
  • OncoTherapy Science
  • Sellas
  • TapImmune

Adjacent Markets